PMX

Primex Finance Announces Community Rewards Campaign With CoinList

Retrieved on: 
Monday, April 8, 2024
Trader, Partnership, Contribution, PMX, Leaderboard, Cryptocurrency

New York, NY, April 08, 2024 (GLOBE NEWSWIRE) -- Primex Finance , a non-custodial protocol for margin trading on decentralized exchanges, announces the launch of a new points-based community rewards initiative in partnership with CoinList .

Key Points: 
  • New York, NY, April 08, 2024 (GLOBE NEWSWIRE) -- Primex Finance , a non-custodial protocol for margin trading on decentralized exchanges, announces the launch of a new points-based community rewards initiative in partnership with CoinList .
  • The goal of the Contribute and Earn Rewards Campaign is to incentivize user engagement, as well as to boost lending and trading activity within the Primex ecosystem.
  • By allocating 2% of the total Primex Token (PMX) supply to the initiative, Primex will distribute Early Primex Token (ePMX) rewards to the best-performing participants.
  • As part of the Contribute and Earn Rewards Campaign, Primex leverages CoinList's established platform and its community to foster ecosystem activity and onboard new lenders and traders to the protocol.

Spectral Medical Chair to Retire From the Board of Directors

Retrieved on: 
Tuesday, April 2, 2024
Sepsis, Chair, Mortality, Septic shock, PMX, TSX, Retirement, Management

Mr. Bihl has been a Director of the Company for 16 years and was appointed to the role of Chairman in 2010.

Key Points: 
  • Mr. Bihl has been a Director of the Company for 16 years and was appointed to the role of Chairman in 2010.
  • Mr. Bihl will step down as Chair, effective April 2, 2024, but will remain a director until his retirement from the board in June.
  • “It has been my pleasure to serve Spectral for 16 years, including the last 14 years as Chairman.
  • I have been fortunate to work with Tony for the last three years and I wish him well for the future,” said Chris Seto, CEO of Spectral Medical.

Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update

Retrieved on: 
Thursday, March 28, 2024
Emory Healthcare, Sepsis, Conference, SAMI, Motivation, Clinical professor, Partnership, Patient, EAA, Mayo Clinic, Mortality, Septic shock, EDEN, University, Spectral, Intensive care unit, Critical care, PMX, AME Publishing Company, TSX, Clinical trial, Nephrology, ICU, FDA, UCLA, Baxter, Marketing, Economics, Hemoperfusion, Pharmaceutical industry

TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update.
  • Dr. John Kellum, Chief Medical Officer of Spectral Medical, stated, “We have witnessed robust enrollment activity to start 2024.
  • addition of two new trial sites in the fourth quarter – the Mayo Clinic and Emory Healthcare.
  • The Company concluded the 2023 year with cash of $2,952,000 compared to $8,414,000 cash on hand as of December 31, 2022.

Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation

Retrieved on: 
Wednesday, February 21, 2024
Baxter International, PMX, Sepsis, Intensive care unit, Amend, Investment, FDA, TSX, U.S. FDA, Risk, Baxter, Patient, Septic shock, United, Partnership, Pharmaceutical industry

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended Agreement”) with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (“Baxter”) (NYSE: BAX), originally entered into in February 2020.

Key Points: 
  • TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, is pleased to announce an extension to its supply and distribution agreement (the “Amended Agreement”) with Baxter Healthcare Corporation, a subsidiary of Baxter International Inc. (“Baxter”) (NYSE: BAX), originally entered into in February 2020.
  • Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”).
  • “Baxter’s continued commitment to Spectral as our exclusive supply and distribution partner being extended for a ten-year period upon U.S. FDA approval provides us with great confidence in our commercialization path,” said Chris Seto, CEO of Spectral Medical.
  • On February 15, 2024, Spectral announced that it had reached the 90-patient enrollment threshold and provided written notification to Baxter of this achievement.

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Retrieved on: 
Thursday, February 15, 2024
Baxter International, PMX, Sepsis, Intensive care unit, Spectral, FDA, TSX, Baxter, Patient, Septic shock, Acceleration, United, Partnership, Pharmaceutical industry

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.

Key Points: 
  • TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.
  • Under the terms of the Company’s Exclusive Distribution Agreement with Baxter International (“Baxter”) (NYSE:BAX), at Interim Enrollment, Baxter has the option to make a second milestone payment to Spectral to maintain its PMX exclusive distribution rights.
  • As such, Spectral has formally notified Baxter of reaching its Interim Enrollment target of 90 patients.
  • “Enrolling patient 90 represents a major milestone in many ways for Spectral as we continue to see acceleration across our Tigris trial sites and building confidence and momentum towards completing the trial,” said Chris Seto, CEO of Spectral Medical.

Spectral Medical Provides Early February Tigris Trial Update

Retrieved on: 
Monday, February 5, 2024
Clinical trial, TSX, University, Septic shock, Patient, PMX, Lipopolysaccharide, Randomized controlled trial, Sepsis

TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Key Points: 
  • TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.
  • Robust enrollment activity continues throughout 2024:
    Six patients enrolled in the month of January, which is the highest monthly enrollment experienced since the start of the Tigris study
    Closing in on the interim enrollment target of 90 patients (“Interim Enrollment”); at Interim Enrollment, Baxter has the option to make the second milestone payment to Spectral to maintain its PMX exclusive distribution rights.
  • Continue to make progress opening an additional six new, high quality clinical sites.
  • “Additionally, with 62 patients to go, we are entering the final push to fully enroll and finish the Tigris trial.”

Spectral Medical Provides January Tigris Trial Update

Retrieved on: 
Tuesday, January 30, 2024
Clinical trial, TSX, University, Septic shock, Patient, PMX, Lipopolysaccharide, Randomized controlled trial, Sepsis

TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Key Points: 
  • TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.
  • University of Texas Health Sciences Center at Houston finalized and executed the Tigris clinical trial agreement; the Company anticipates another Texas-based site to execute its clinical trial agreement in the coming days.
  • The robust enrollment activity throughout January puts Spectral within striking distance of our interim enrollment milestone of 90 patients, which is expected to play as a major catalyst for the Company,” said Chris Seto, Chief Executive Officer of Spectral Medical.
  • “Additionally, with 65 patients to go, we are entering the final push to fully enroll and finish the Tigris trial.”

Spectral Medical Enrolls Patient 82 in Its Phase 3 FDA Tigris Septic Shock Trial

Retrieved on: 
Wednesday, January 10, 2024
Baxter International, PMX, Lipopolysaccharide, Septic shock, Mortality, Patient, Sepsis, TSX, Randomized controlled trial, Nursing

TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Key Points: 
  • TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.
  • Initiated 2024 with robust site activity to start the new year:
    Enrolled patient 82 during the first week of January.
  • This resumes the strong enrollment into Tigris which we experienced since holding our Investigator Meeting this past May.
  • “Additionally, with 68 patients to go, we are entering the final push to fully enroll and finish the Tigris trial.”

iHeartMedia and Magnite Unify Access to Broadcast and Digital Audio, Providing Advertisers with a Direct Path to Premium Inventory

Retrieved on: 
Tuesday, January 9, 2024
PMX, Advertising, Trust, Radio, Partnership, IHeartRadio, Environment, Television, IHeartMedia, Publicis, Music

Built from a custom implementation of Magnite’s SpringServe ad serving technology, the marketplace enables advertisers to transact with a data-driven approach via real-time-bidding across iHeartMedia’s vast broadcast and digital audio inventory through a single activation channel.

Key Points: 
  • Built from a custom implementation of Magnite’s SpringServe ad serving technology, the marketplace enables advertisers to transact with a data-driven approach via real-time-bidding across iHeartMedia’s vast broadcast and digital audio inventory through a single activation channel.
  • IHeartMedia reaches 90 percent of all US adults monthly with its broadcast stations alone and its streaming radio and podcasts reach 57 million consumers with high-quality ad-enabled content, the largest reach of any digital audio company.
  • “With today’s consumers spending a third of their media time with audio, expanding programmatic’s access to iHeart’s audio assets is imperative for the industry,” said Brian Kaminsky, Chief Data Officer and President of Revenue Strategies for iHeartMedia.
  • “We’ve worked closely with iHeartMedia to develop bespoke and new-to-market solutions for podcast and audio.

Spectral Medical Provides Tigris Trial Update

Retrieved on: 
Thursday, December 14, 2023
Sepsis, EDEN, Septic shock, FDA, Mortality, Randomized controlled trial, Observational study, Lipopolysaccharide, PMX, TSX, Patient, Baxter International, Pharmaceutical industry

TORONTO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Key Points: 
  • TORONTO, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.
  • Currently 20 Tigris trial sites, with near term onboarding of new, high quality clinical sites.
  • Clinical Trial Agreements (“CTA”) either executed or in final revision phase at six new clinical sites.
  • Dr. John Kellum, Chief Medical Officer of Spectral, commented, “Since the end of October, we experienced strong enrollment into Tigris despite the U.S. Thanksgiving holiday, with seven patient enrollments in the last eight weeks.